IL-6 (considered as prime culprit) and other cytokines (TNF-alpha, IFN-gamma, IL-1, IL-2 etc) are associated with COVID-19 related cytokine storm and further morbidity and mortality . The current research is mainly focusing on costly monoclonal antibodies like Tocilizumab, siltuximab and sarilumab (IL-6 inhibitors) . These are injectable drugs and are also associated with troublesome adverse effects.
On the other hand existing age old drugs like tetracyclines have multifaceted anticytokine actions (they inhibit IL-6, TNF-alpha, IFN-gamma and other cytokines) and they also offer other benefits in terms of cost, orally available, and their safety profile is well established. Efforts should be made to reposition these drugs particularly in developing countries to save the money and time . Drug
re- purposing could be a very useful approach in this aspect.
Kindly give your input